Purchase this article with an account.
Freekje van Asten, Maroeska Rovers, Yara Lechanteur, Dzenita Smailhodzic, Philipp Muether, Anneke Den Hollander, Sascha Fauser, Carel Hoyng, Gert Jan van der Wilt, B. Jeroen Klevering; Predicting Non-response to Ranibizumab in Patients with Neovascular Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2013;54(15):246.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To validate known and to determine new predictors of non-response to ranibizumab in patients with neovascular age-related macular degeneration (AMD) and to incorporate these factors into a prediction rule.
This multicenter, observational case series study included 394 patients treated with ranibizumab for neovascular AMD. We performed genetic analysis for single nucleotide polymorphisms in AMD-associated genes and collected questionnaires regarding environmental factors and disease history. The primary outcome was non-response to treatment, which we defined as a loss of visual acuity of 30% of letters or more on EDTRS chart.
Of the 394 patients, 47 were classified as non-responder. Independent predictors for non-response were: age, baseline visual acuity, diabetes mellitus and accumulation of risk alleles in the CFH, ARMS2 and VEGF-A genes. The area under the receiver operating characteristic curve was 0.77 (95% confidence interval: 0.70 - 0.84). We derived a clinical prediction rule, with possible total risk scores ranging from 0 to 21 points. The absolute risk of non-response varied from 2% to 53% between risk score groups.
A straightforward clinical prediction rule can aid clinicians identifying AMD patients with an increased or decreased likelihood of non-response to treatment with ranibizumab.
This PDF is available to Subscribers Only